ILS2024 Time Table

Dec.2th - 5th
ToranomonHills & Online (partial)
All ILS2024 Power Matching account holders are welcome to attend for free!
12/2 mon
12/3 tue
12/4 wed
12/5 thur
Pitches
Seminars
Meetups
Exhibits
Application Category

Open

5th Dec. 10:30 | 12:30
5th Dec. 10:30 - 12:30
Toranomon Hills 5F Hall A1
Online: Channel2
  • Startup Pitches
  • Lang: Only Japanese (no simultaneous interpretation)
NEDO Dream Pitch [Day 2] by Startups
  • NEDO Startup Pitch
Startups supported by NEDO will be making business pitches!
21 companies from business fields such as life sciences, decarbonization/SDGs, digital health, and food will be on stage!
✓ Reserve
\ NOW ON STAGE /

Development of treatments for central nervous system disorders using novel human neural stem cells ""oligogenys""

Using the novel human neural stem cells ""Oligogeny"", we will conduct clinical development of regenerative medicine products (cell preparations) and exosome preparations for the treatment of central nervous system diseases such as spinal cord injury, multiple sclerosis, and Alzheimer's disease.

Development of treatments for central nervous system disorders using novel human neural stem cells ""oligogenys""

Using the novel human neural stem cells ""Oligogeny"", we will conduct clinical development of regenerative medicine products (cell preparations) and exosome preparations for the treatment of central nervous system diseases such as spinal cord injury, multiple sclerosis, and Alzheimer's disease.
Oligogen Inc
Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine
\ NOW ON STAGE /

Making antibodies in test tubes --- Compatible with animal welfare

Changing the world of antibody production. This is one of EME's missions. We are not simply advocating not using animals to produce antibodies for animal welfare, because the in vitro screening method opens new possibilities for obtaining new functional antibodies. We are now focusing on VHH antibody applications other than pharmaceuticals.

Making antibodies in test tubes --- Compatible with animal welfare

Changing the world of antibody production. This is one of EME's missions. We are not simply advocating not using animals to produce antibodies for animal welfare, because the in vitro screening method opens new possibilities for obtaining new functional antibodies. We are now focusing on VHH antibody applications other than pharmaceuticals.
Naoto Nemoto│Epsilon Molecular Engineering, Chief Executive Officer
Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine
\ NOW ON STAGE /

Contactless Sleep Apnea Treatment Device with Millimeter-Wave Radar

We develop medical devices to diagnose and treat sleep disorders like sleep apnea (SAS) using non-contact sensing and digital signal processing. We are currently developing a non-contact respiratory monitor, and plan to start selling it from next year. We will provide a non-contact and privacy-conscious solution.

Contactless Sleep Apnea Treatment Device with Millimeter-Wave Radar

We develop medical devices to diagnose and treat sleep disorders like sleep apnea (SAS) using non-contact sensing and digital signal processing. We are currently developing a non-contact respiratory monitor, and plan to start selling it from next year. We will provide a non-contact and privacy-conscious solution.
Hirofumi Taki│MaRI Co., Ltd., CEO
Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine
\ NOW ON STAGE /

Robotic assisted microsurgery system

F.MED is specialized in developing robotic microsurgery assist systems to support precise handling of microscopic tools, which conventional robots are unable to achieve. The robot replicates surgeon's gestures with motion scale down and hand tremor control to maximize both safety and effectiveness.

Robotic assisted microsurgery system

F.MED is specialized in developing robotic microsurgery assist systems to support precise handling of microscopic tools, which conventional robots are unable to achieve. The robot replicates surgeon's gestures with motion scale down and hand tremor control to maximize both safety and effectiveness.
Keita Shimonura│F.MED Co., Ltd.,
Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine
\ NOW ON STAGE /

Self-measuring tonometer to prevent blindness due to glaucoma

Glaucoma is defined as a disease characterized by functional and structural abnormalities of the eye that have characteristic changes in the optic nerve and visual field, and in which optic nerve damage can usually be improved or suppressed by sufficient lowering of intraocular pressure (Japan Glaucoma Guideline). Glaucoma is one of the leading causes of blindness in Japan. A detailed glaucoma epidemiological study conducted from 2000 to 2002 (Iwase et al. Tajimi Study. Ophthalmology. 2004) showed that the prevalence of glaucoma in Japanese people aged 40 years or older was 5.0%, with an estimated number of patients in 2016 of 4.65 million. In glaucoma, the damage gradually progresses without the patient's awareness, so it is important to prevent or suppress the progression of the damage through early detection and early treatment. Lowering intraocular pressure is the only treatment for glaucoma, and eye drops are used, but intraocular pressure fluctuates during the day, making it difficult to administer eye drops at the appropriate time. Although it is desirable to always know the intraocular pressure, patients do not have frequent access to medical institutions and are therefore not able to always keep track of the intraocular pressure. If patients can measure intraocular pressure easily and safely at home, (1) it will be easier to evaluate the effectiveness of treatment and medication adherence will improve. In other words, behavioral changes can be expected. (2) It will contribute to further elucidation of the pathology of glaucoma. (3) It will reduce congestion in ophthalmology clinics. (4) It will lead to reduced medical costs if eye drops to lower intraocular pressure are used only when necessary (when intraocular pressure rises). This device measures intraocular pressure through the eyelid, so it can be measured easily and safely. It will also achieve an overwhelmingly low price. The customers are glaucoma patients, who are the end users of this device. In the future, tonometers will be distributed at home electronics retailers like blood pressure monitors. With the recent deregulation of online medical care and remote health medical consultations, patients can now receive interviews, examinations, consultations, and treatments without visiting a medical institution. This device has excellent compatibility with online medical care and allows doctors and patients to share intraocular pressure data, making it a good fit for online glaucoma treatment and an indispensable medical device.

Self-measuring tonometer to prevent blindness due to glaucoma

Glaucoma is defined as a disease characterized by functional and structural abnormalities of the eye that have characteristic changes in the optic nerve and visual field, and in which optic nerve damage can usually be improved or suppressed by sufficient lowering of intraocular pressure (Japan Glaucoma Guideline). Glaucoma is one of the leading causes of blindness in Japan. A detailed glaucoma epidemiological study conducted from 2000 to 2002 (Iwase et al. Tajimi Study. Ophthalmology. 2004) showed that the prevalence of glaucoma in Japanese people aged 40 years or older was 5.0%, with an estimated number of patients in 2016 of 4.65 million. In glaucoma, the damage gradually progresses without the patient's awareness, so it is important to prevent or suppress the progression of the damage through early detection and early treatment. Lowering intraocular pressure is the only treatment for glaucoma, and eye drops are used, but intraocular pressure fluctuates during the day, making it difficult to administer eye drops at the appropriate time. Although it is desirable to always know the intraocular pressure, patients do not have frequent access to medical institutions and are therefore not able to always keep track of the intraocular pressure. If patients can measure intraocular pressure easily and safely at home, (1) it will be easier to evaluate the effectiveness of treatment and medication adherence will improve. In other words, behavioral changes can be expected. (2) It will contribute to further elucidation of the pathology of glaucoma. (3) It will reduce congestion in ophthalmology clinics. (4) It will lead to reduced medical costs if eye drops to lower intraocular pressure are used only when necessary (when intraocular pressure rises). This device measures intraocular pressure through the eyelid, so it can be measured easily and safely. It will also achieve an overwhelmingly low price. The customers are glaucoma patients, who are the end users of this device. In the future, tonometers will be distributed at home electronics retailers like blood pressure monitors. With the recent deregulation of online medical care and remote health medical consultations, patients can now receive interviews, examinations, consultations, and treatments without visiting a medical institution. This device has excellent compatibility with online medical care and allows doctors and patients to share intraocular pressure data, making it a good fit for online glaucoma treatment and an indispensable medical device.
Paul Bridenbaugh│Toneasy, Inc.,
Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine
\ NOW ON STAGE /

Clinical study of the novel FMT method achieved by NanoPicoBubble technology

We have developed a novel Fecal Microbiota Transplantation method (FMT) using NanoPicoBubble technology (patented technology). We are conducting a " specified clinical trials" on the therapeutic effects of this novel FMT on children with autism spectrum disorder, and it has been confirmed that approximately 70% of the study subjects progress to a milder stage of the condition.

Clinical study of the novel FMT method achieved by NanoPicoBubble technology

We have developed a novel Fecal Microbiota Transplantation method (FMT) using NanoPicoBubble technology (patented technology). We are conducting a " specified clinical trials" on the therapeutic effects of this novel FMT on children with autism spectrum disorder, and it has been confirmed that approximately 70% of the study subjects progress to a milder stage of the condition.
Mikiko Tanaka│Shinbiosis Corporation, representative director
Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine
\ NOW ON STAGE /

Liquid metal switch that reduces heat generation inside the switch by 1/100

Conventional switches cannot increase the contact pressure because they cut off instantly. In other words, they cannot reduce the contact resistance. Nevertheless, the maximum current flows through the breaker, which always generates heat. Liquid metal switches can reduce this power loss. They are suitable for data centers where power consumption is increasing due to generative AI.

Liquid metal switch that reduces heat generation inside the switch by 1/100

Conventional switches cannot increase the contact pressure because they cut off instantly. In other words, they cannot reduce the contact resistance. Nevertheless, the maximum current flows through the breaker, which always generates heat. Liquid metal switches can reduce this power loss. They are suitable for data centers where power consumption is increasing due to generative AI.
Kenichi Harakawa│ExH Corporation, CEO
Renewable Energy / Decarbonization / SDGs / Smart Grid
\ NOW ON STAGE /

Bioproduction system using photoswitching proteins

Due to the awareness of the crisis of climate change, industrial activities that are conscious of sustainability are becoming more important, and expectations for bio-manufacturing are also becoming higer worldwide. MiiBio, a startup from the University of Tokyo, is using light-switching protein technology to globally deploy the mii-Bioprocess, a production system useful for mass production of bio-manufacturing.

Bioproduction system using photoswitching proteins

Due to the awareness of the crisis of climate change, industrial activities that are conscious of sustainability are becoming more important, and expectations for bio-manufacturing are also becoming higer worldwide. MiiBio, a startup from the University of Tokyo, is using light-switching protein technology to globally deploy the mii-Bioprocess, a production system useful for mass production of bio-manufacturing.
Kensho Hayamizu│miibio, Inc.,
Renewable Energy / Decarbonization / SDGs / Smart Grid
\ NOW ON STAGE /

New Energy System Expanding from EV Charging Service WeCharge

Introducing the new energy system from WeCharge EV charging service, we'll explain how installing one outlet per parking space contributes to a decarbonized society. We'll demonstrate our innovative Plug & Charge system, utilizing advanced eNFC technology, and present Ubiden's vision for electricity's future.

New Energy System Expanding from EV Charging Service WeCharge

Introducing the new energy system from WeCharge EV charging service, we'll explain how installing one outlet per parking space contributes to a decarbonized society. We'll demonstrate our innovative Plug & Charge system, utilizing advanced eNFC technology, and present Ubiden's vision for electricity's future.
Norio Yamaguchi│Ubiden, CEO & Co-founder
Renewable Energy / Decarbonization / SDGs / Smart Grid
\ NOW ON STAGE /

Computational enzyme design for food, environment and energy industries

digzyme Inc. is a startup originating from the Tokyo Institute of Technology that leverages bioinformatics to efficiently design and scale the production of enzymes for various industrial applications. Our mission is to innovate enzyme solutions that enhance processes across the food and environmental energy industries. In the food industry, we focus on the development of new food ingredients and enzymes that improve cost efficiency and process optimization. Our solutions help companies create novel food products and streamline production methods, ensuring better use of resources and reducing costs. For the environmental energy industry, we specialize in developing enzymes for milder synthesis of raw materials, such as those used in cosmetics, engineering plastics, and fragrances. Additionally, we are actively working on enzyme solutions for waste management, targeting improved waste breakdown and disposal methods that contribute to a more sustainable environment.

Computational enzyme design for food, environment and energy industries

digzyme Inc. is a startup originating from the Tokyo Institute of Technology that leverages bioinformatics to efficiently design and scale the production of enzymes for various industrial applications. Our mission is to innovate enzyme solutions that enhance processes across the food and environmental energy industries. In the food industry, we focus on the development of new food ingredients and enzymes that improve cost efficiency and process optimization. Our solutions help companies create novel food products and streamline production methods, ensuring better use of resources and reducing costs. For the environmental energy industry, we specialize in developing enzymes for milder synthesis of raw materials, such as those used in cosmetics, engineering plastics, and fragrances. Additionally, we are actively working on enzyme solutions for waste management, targeting improved waste breakdown and disposal methods that contribute to a more sustainable environment.
Naoki Watarai│digzyme Inc., CEO
Renewable Energy / Decarbonization / SDGs / Smart Grid
\ NOW ON STAGE /

Bio-based chemicals contribute to the realization of a Circular Society

BioPhenolics is committed to transitioning from the petrochemical industry to a bio-based manufacturing industry. Our company is developing technology that produces aromatic biochemicals through fermentation using genetically engineered microorganisms, with biomass as the raw material. These biochemicals fix carbon dioxide from the atmosphere, making them a key resource for decarbonized products.

Bio-based chemicals contribute to the realization of a Circular Society

BioPhenolics is committed to transitioning from the petrochemical industry to a bio-based manufacturing industry. Our company is developing technology that produces aromatic biochemicals through fermentation using genetically engineered microorganisms, with biomass as the raw material. These biochemicals fix carbon dioxide from the atmosphere, making them a key resource for decarbonized products.
NUKI Noriyuki│BioPhenolics Inc., CEO
Renewable Energy / Decarbonization / SDGs / Smart Grid
\ NOW ON STAGE /

The ultimate potential of light: laser fusion to revolutionize energy and create new industries

A startup from Osaka University that aims to realize laser fusion energy. We develop and manufacture laser fusion reactors and their components. We also work on industrial applications such as laser processing, space debris capture and removal, and seawater desalination.

The ultimate potential of light: laser fusion to revolutionize energy and create new industries

A startup from Osaka University that aims to realize laser fusion energy. We develop and manufacture laser fusion reactors and their components. We also work on industrial applications such as laser processing, space debris capture and removal, and seawater desalination.
Kazuki Matsuo│EX-Fusion Inc., CEO
Renewable Energy / Decarbonization / SDGs / Smart Grid
\ NOW ON STAGE /

Supporting mental health with VR and AI

We develop VR solutions for mental health. We are mainly developing ① VR DTx for depression and ② solutions to improve diseases and symptoms related to cognitive and attentional functions by utilizing the know-how gained through ①.

Supporting mental health with VR and AI

We develop VR solutions for mental health. We are mainly developing ① VR DTx for depression and ② solutions to improve diseases and symptoms related to cognitive and attentional functions by utilizing the know-how gained through ①.
Masayo Matsumura│BiPSEE, CEO
Digital Health / Well-being
\ NOW ON STAGE /

To the world where you can see what you want to see with autofocal glasses

Our company is the startup that utilizes liquid crystal lens technology developed at the Graduate School of Engineering, Osaka University, and is aimed at everyone, whether you are currently struggling to see or want to see new things that you have never seen before. We are developing autofocal glasses with the vision of making things visible.

To the world where you can see what you want to see with autofocal glasses

Our company is the startup that utilizes liquid crystal lens technology developed at the Graduate School of Engineering, Osaka University, and is aimed at everyone, whether you are currently struggling to see or want to see new things that you have never seen before. We are developing autofocal glasses with the vision of making things visible.
Sunri Lee│Elcyo, CEO
Digital Health / Well-being
\ NOW ON STAGE /

Creating a society with zero fall accidents with the "RitsuiNenrei®" measuring device StA²BLE

"StA²BLE" quantifies fall-risk for the first time worldwide by providing sensory stimulation to the fingertips as well as AI technology for analysis. It is an innovative technology that can provide wider coverage in health checkups. It enables a comprehensive assessment of sensory and physical abilities of fall-risk which could not be measured up to now and calculates "RitsuiNenrei®" (Age at Standing, strength to change in sensory stimuli expressed as age) in one minute.

Creating a society with zero fall accidents with the "RitsuiNenrei®" measuring device StA²BLE

"StA²BLE" quantifies fall-risk for the first time worldwide by providing sensory stimulation to the fingertips as well as AI technology for analysis. It is an innovative technology that can provide wider coverage in health checkups. It enables a comprehensive assessment of sensory and physical abilities of fall-risk which could not be measured up to now and calculates "RitsuiNenrei®" (Age at Standing, strength to change in sensory stimuli expressed as age) in one minute.
Keisuke Shima│UNTRACKED, CEO
Digital Health / Well-being
\ NOW ON STAGE /

Digital blood sugar control

We are developing an AI that predicts blood glucose trends through waveform analysis of post-meal blood glucose levels. This technology makes it possible to comprehensively predict data from medical to healthcare.

Digital blood sugar control

We are developing an AI that predicts blood glucose trends through waveform analysis of post-meal blood glucose levels. This technology makes it possible to comprehensively predict data from medical to healthcare.
THE PHAGE, Inc.
Digital Health / Well-being
\ NOW ON STAGE /

Introducing commercial product development using genome editing breeding

Seturo Tech, a startup company spun out of Tokushima University, is working on a business that utilizes genome editing technology. It is developing a research support business that provides genome-edited mice and genome-edited cells to companies working on drug discovery research, and a PAGEs business that works on breeding for companies in the agricultural and livestock industries. In particular, the PAGEs business has a track record of development with large companies that participate in ILS, and there are also cases where companies that are entering the agricultural field as a new business are working on breeding using genome editing technology as their killer content. In this pitch, we will introduce some of the efforts of the PAGEs business and explain how genome editing technology can be used in new product development.

Introducing commercial product development using genome editing breeding

Seturo Tech, a startup company spun out of Tokushima University, is working on a business that utilizes genome editing technology. It is developing a research support business that provides genome-edited mice and genome-edited cells to companies working on drug discovery research, and a PAGEs business that works on breeding for companies in the agricultural and livestock industries. In particular, the PAGEs business has a track record of development with large companies that participate in ILS, and there are also cases where companies that are entering the agricultural field as a new business are working on breeding using genome editing technology as their killer content. In this pitch, we will introduce some of the efforts of the PAGEs business and explain how genome editing technology can be used in new product development.
Shinichiro Takezawa│Setsuro Tech, CEO
Food / Food Production / Agriculture / Fisheries
\ NOW ON STAGE /

bitBiome's Biomanufacturing: Unlocking the Full Potential of Microbes

bitBiome is a biotechnology company dedicated to unlocking the full potential of Earth’s microbes to drive the future of the bioeconomy. By leveraging our world-leading genome database and comprehensive enzyme discovery and engineering platform, we are committed to advancing existing biomanufacturing industries and creating new ones by delivering unique sequences and enzymes that cannot be found anywhere else.

bitBiome's Biomanufacturing: Unlocking the Full Potential of Microbes

bitBiome is a biotechnology company dedicated to unlocking the full potential of Earth’s microbes to drive the future of the bioeconomy. By leveraging our world-leading genome database and comprehensive enzyme discovery and engineering platform, we are committed to advancing existing biomanufacturing industries and creating new ones by delivering unique sequences and enzymes that cannot be found anywhere else.
Takuya Yoda│bitBiome, Business Development
Food / Food Production / Agriculture / Fisheries
\ NOW ON STAGE /

AWL: Leading Global DX with No.1 Edge AI Video Analytics Solutions

AWL, a startup from Hokkaido University, leads the industry with its edge AI video analytics technology. Showcasing successes in store efficiency and security, our vision for future tech innovations and global expansion. Our solutions cater to retail, offices, facilities, and manufacturing, providing actionable insights for your challenges.

AWL: Leading Global DX with No.1 Edge AI Video Analytics Solutions

AWL, a startup from Hokkaido University, leads the industry with its edge AI video analytics technology. Showcasing successes in store efficiency and security, our vision for future tech innovations and global expansion. Our solutions cater to retail, offices, facilities, and manufacturing, providing actionable insights for your challenges.
北出 宗治│AWL, CEO
Retail
\ NOW ON STAGE /

A quantum platform that solves problems in a wide range of fields

We develop middleware for combinatorial optimization problems that are difficult to calculate using conventional methods, and provide APIs for optimization problems in logistics delivery plans, AGV control in warehouses, and MaaS vehicle dispatch, based on our middleware.

A quantum platform that solves problems in a wide range of fields

We develop middleware for combinatorial optimization problems that are difficult to calculate using conventional methods, and provide APIs for optimization problems in logistics delivery plans, AGV control in warehouses, and MaaS vehicle dispatch, based on our middleware.
Natsuki Mastsui│Jij,
Other
✓ Reserve

Close

Share with ... Facebook X Linkedin Copy URL to Clipbord